Patent Describes Isolated Antibody for Treating Cancer and Methods for Producing it

Strategic Insights -

The patent titled "Anti-TREM2 Antibodies and Related Methods" has been published online on September 30, 2025. The inventors, Aritra Pal, Leonard G. Presta, Venkataraman Sriram, Michel Streuli, and the assignee Portsmouth Merger Sub II LLC, describe an isolated antibody that binds to human TREM2 and competes with the 37017 antibody for binding to mouse TREM2.

The antibody has several specific sequences for its CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 regions. The claims also describe various embodiments of the isolated polynucleotide or set of polynucleotides encoding the antibody, including those with specific VH and VL sequences.

Key Takeaways:

  • The patent describes a novel isolated antibody that binds to human TREM2 and competes with the 37017 antibody for binding to mouse TREM2.
  • The antibody has specific sequences for its CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 regions.
  • The claims include various embodiments of the isolated polynucleotide or set of polynucleotides encoding the antibody, including those with specific VH and VL sequences.
  • The patent references related patent applications, including PCT/US2015/052682 and PCT/US2016/054104, which are herein incorporated by reference in their entirety.
  • The inventors' summary states that the described antibody may be used to treat cancer, and the claims include methods for producing the antibody using a host cell.
  • The patent describes various specific sequences for the heavy and light chain regions of the antibody.
  • The patent also recites claims related to a vector or set of vectors comprising the polynucleotide or set of polynucleotides encoding the antibody.

Statistics:

  • The patent was filed on October 7, 2022.
  • The patent was published online on September 30, 2025.
  • The described antibody has a KD of less than or equal to about 1, 2, 3, 4, or 5 x 10^(-9) M, as measured by SPR assay.

Sources:

  • PCT/US2015/052682 (filing date: September 28, 2015)
  • PCT/US2016/054104 (filing date: September 28, 2016)
  • de Visser et al. (Cancer Immunol Immunother, 2008; 57:1531-9)
  • Hanada et al. (Int J Urol 2000; 7:263-9)
  • Yao et al. (Clin Cancer Res, 520, 2001; 7:4021-6)
  • Ruffell et al. (PNAS, 523, 2012; 109:2796-801)
  • Bell et al. (J Exp Med, 555, 1999; 190:1417-26)